Investors

OvaScience is a global fertility company dedicated to improving treatment options for women around the world.

OVAS (Common Stock)
Price & Exchange
$1.52
NASDAQ
Change (%)
0.00 (0.00%)
Volume
142,309
07/24/17      4:00 p.m. ET

Minimum 20 minute delay
Refresh quote

Investor Overview

Recent News

More »
DateTitle 
06/21/17OvaScience Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 21, 2017-- OvaScience℠, Inc. (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an inducement award to its newly appointed Chief Executive Officer Elect, Christopher Kroeger. The award was approved by OvaScience’s Compensation Committee on June 21, 2017 as an inducement material to him entering into employment w... 
Printer Friendly Version
06/21/17OvaScience Appoints Christopher Kroeger, M.D., M.B.A., as Chief Executive Officer
– Dr. Kroeger's Combined Business and Medical Experience Ideally Suited to Drive Company’s OvaTure and OvaPrime-Focused Strategy – – Company Restructures Organization to Align with R&D Efforts and Extend Cash Runway into Q1 2020, Enabling Key 2019 Milestones – WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 21, 2017-- OvaScience℠, Inc. (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new trea... 
Printer Friendly Version
06/13/17OvaScience Completes Enrollment of 70 Patients in OvaPrime Clinical Study in Women with Primary Ovarian Insufficiency or Poor Ovarian Response
– Initial Data from First 20 Patients Expected by Year-End 2017 – WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 13, 2017-- OvaScienceSM Inc. (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced it has completed enrollment of 70 patients in its ongoing clinical study of the OvaPrimeSM treatment, designed to assess the safety of OvaPrime in women with either prim... 
Printer Friendly Version
05/09/17OvaScience Reports First Quarter 2017 Financial Results
–Fertilization of Bovine EggPC Cell-Derived Egg in OvaTure Program on Track for Year-End– –OvaPrime Clinical Trial Progressing Toward Year-End Initial Readout– –Robust Financial Position Supports Corporate Strategy into 1Q19– –Conference Call Today at 4:30 p.m. ET– WALTHAM, Mass.--(BUSINESS WIRE)--May 9, 2017-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercializ... 
Printer Friendly Version

Upcoming Events

More »
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources